Download PDF
AJP Rep 2016; 06(01): e125-e128
DOI: 10.1055/s-0036-1579539
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome

Antonio F. Saad   *
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, Texas
,
Jorge Roman   *
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, Texas
,
Aaron Wyble
2   Division of Transfusion Medicine, Department of Pathology, The University of Texas Medical Branch, Galveston, Texas
,
Luis D. Pacheco
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, Texas
3   Division of Surgical Critical Care, Department of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas
› Author Affiliations
Further Information

Publication History

05 December 2015

16 December 2015

Publication Date:
16 March 2016 (online)

Also available at
   Permissions and Reprints

Précis

Introduction Early diagnosis of atypical uremic–hemolytic syndrome may be challenging during the puerperium period. Correct diagnosis and timely management are crucial to improve outcomes.

Background Pregnancy-associated atypical hemolytic-uremic syndrome (p-aHUS) is a rare condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Triggered by pregnancy, genetically predisposed women develop the syndrome, leading to a disastrous hemolytic disease characterized by diffuse endothelial damage and platelet consumption. This disease is a life-threatening condition that requires prompt diagnosis and therapy.

Case A 19-year-old G1P1 Caucasian female with suspicion of HELLP syndrome was treated at our facility for severe thrombocytopenia and acute kidney injury. A diagnosis of atypical uremic–hemolytic syndrome was later confirmed. The patient's condition improved with normalization of platelets and improvement in kidney function after 14 days of plasmapheresis. She was subsequently treated with eculizumab, a monoclonal antibody against C5. The patient tolerated well the therapy and is currently in remission.

Conclusion Diagnosis of p-aHUS is challenging, as it can mimic various diseases found during pregnancy and the postpartum. Plasma exchange should be promptly initiated within 24 hours of diagnosis. Eculizumab has risen to become an important tool to improve long-term comorbidities and mortality in this group population.

Keywords

atypical hemolytic-uremic syndrome - eculizumab - pregnancy - management

* Both authors have contributed equally.


 

  • References

  • 1 Dashe JS, Ramin SM, Cunningham FG. The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol 1998; 91 (5, Pt 1) 662-668
    CrossrefPubMedGoogle Scholar
  • 2 Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16 (4) 1035-1050
    CrossrefPubMedGoogle Scholar
  • 3 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361 (17) 1676-1687
    CrossrefPubMedGoogle Scholar
  • 4 Fakhouri F, Roumenina L, Provot F , et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010; 21 (5) 859-867
    CrossrefPubMedGoogle Scholar
  • 5 Faguer S, Huart A, Frémeaux-Bacchi V, Ribes D, Chauveau D. Eculizumab and drug-induced haemolytic-uraemic syndrome. Clin Kidney J 2013; 6 (5) 484-485
    CrossrefPubMedGoogle Scholar
  • 6 Legendre CM, Licht C, Muus P , et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368 (23) 2169-2181
    CrossrefPubMedGoogle Scholar
  • 7 Caprioli J, Noris M, Brioschi S , et al; International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108 (4) 1267-1279
    CrossrefPubMedGoogle Scholar